Monthly Prescribing Reference9h
Romvimza Approved for Symptomatic Tenosynovial Giant Cell Tumor
The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...
PharmaTimes4d
FDA approves Deciphera’s Romvimza for rare tumour type
The US Food and Drug Administration (FDA) has approved Deciphera Pharmaceuticals’ Romvimza (vimseltinib) to treat adults with ...
News Medical on MSN4d
FDA approves Romvimza for tenosynovial giant cell tumor (TGCT)
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition ...
BioWorld5d
Deciphera’s Romvimza wins FDA nod for tenosynovial giant cell tumors
Becoming the second drug approved by the U.S. FDA for tenosynovial giant cell tumors, Deciphera Pharmaceuticals Inc.’s oral ...
MedCity News6d
Ono Pharma Drug Acquired in $2.4B Deal Wins FDA Approval for Treating Rare Type of Tumor
The twice-weekly capsule will be marketed under the brand name Romvimza. TGCT stems from a genetic abnormality that results in overexpression of a protein called colony-stimulating factor receptor.
Pharmabiz3d
Ono Pharmaceutical’s vimseltinib to treat tenosynovial giant cell tumour gets US FDA approval
Ono Pharmaceutical’s vimseltinib to treat tenosynovial giant cell tumour gets US FDA approval: Osaka Friday, February 21, 2025, 15:00 Hrs [IST] Ono Pharmaceutical, one of the la ...
pharmaphorum5d
Ono poised to join Daiichi in TGCT market after FDA nod
Ono Pharmaceutical has claimed FDA approval for Romvimza as a treatment for tenosynovial giant cell tumour (TGCT), setting up a market tussle with Daiichi Sankyo. CSF-1R inhibitor Romvimza ...